FDA Grants Accelerated Approval to Loncastuximab Tesirine-lpyl for R/R LBCL

On April 23, 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval to loncastuximab tesirine-lpyl for adult patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low grade lymphoma, and high-grade B-cell lymphoma.

Read the FDA announcement.

Read ADC Therapeutics announcement.

Posted 4/26/2021